Literature DB >> 19383906

Catecholamines regulate tumor angiogenesis.

Debanjan Chakroborty1, Chandrani Sarkar, Biswarup Basu, Partha Sarathi Dasgupta, Sujit Basu.   

Abstract

Among the regulators of angiogenesis, catecholamine neurotransmitters are of recent interest because of their opposite roles in the regulation of tumor neovascularization. Norepinephrine and epinephrine by acting through specific adrenoceptors increase the synthesis of proangiogenic factors, and thereby, promote tumor growth. In contrast, dopamine acting via its specific D(2) receptors inhibits tumor growth by suppressing the actions of vascular permeability factor/vascular endothelial growth factor-A on both tumor endothelial and bone marrow-derived endothelial progenitor cells. These reports identify novel endogenous regulators of tumor angiogenesis and also indicate a new and an inexpensive class of antiangiogenic drugs for the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19383906     DOI: 10.1158/0008-5472.CAN-08-4289

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  59 in total

1.  Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer.

Authors:  D C Borcherding; W Tong; E R Hugo; D F Barnard; S Fox; K LaSance; E Shaughnessy; N Ben-Jonathan
Journal:  Oncogene       Date:  2015-10-19       Impact factor: 9.867

Review 2.  Sympathetic nervous system regulation of the tumour microenvironment.

Authors:  Steven W Cole; Archana S Nagaraja; Susan K Lutgendorf; Paige A Green; Anil K Sood
Journal:  Nat Rev Cancer       Date:  2015-09       Impact factor: 60.716

3.  hTERT mediates norepinephrine-induced Slug expression and ovarian cancer aggressiveness.

Authors:  M J Choi; K H Cho; S Lee; Y J Bae; K J Jeong; S Y Rha; E J Choi; J H Park; J M Kim; J-S Lee; G B Mills; H Y Lee
Journal:  Oncogene       Date:  2014-08-25       Impact factor: 9.867

4.  Systems pharmacogenomics - gene, disease, drug and placebo interactions: a case study in COMT.

Authors:  Kathryn T Hall; Joseph Loscalzo; Ted J Kaptchuk
Journal:  Pharmacogenomics       Date:  2019-05       Impact factor: 2.533

5.  Changes in urinary metabolic profiles of colorectal cancer patients enrolled in a prospective cohort study (ColoCare).

Authors:  David B Liesenfeld; Nina Habermann; Reka Toth; Robert W Owen; Eva Frei; Jürgen Staffa; Petra Schrotz-King; Karel D Klika; Cornelia M Ulrich
Journal:  Metabolomics       Date:  2014-12-20       Impact factor: 4.290

6.  Expression of β-adrenergic receptors in pediatric malignant brain tumors.

Authors:  Iacopo Sardi; Laura Giunti; Cecilia Bresci; Anna Maria Buccoliero; Duccio Degl'innocenti; Stefania Cardellicchio; Gianna Baroni; Francesca Castiglione; Martina DA Ros; Patrizio Fiorini; Sabrina Giglio; Lorenzo Genitori; Maurizio Aricò; Luca Filippi
Journal:  Oncol Lett       Date:  2012-10-23       Impact factor: 2.967

7.  The albino mutation of tyrosinase alters ocular angiogenic responsiveness.

Authors:  Michael S Rogers; Irit Adini; Aaron F McBride; Amy E Birsner; Robert J D'Amato
Journal:  Angiogenesis       Date:  2013-02-20       Impact factor: 9.596

8.  Sympathetic Neurotransmitters and Tumor Angiogenesis-Link between Stress and Cancer Progression.

Authors:  Jason Tilan; Joanna Kitlinska
Journal:  J Oncol       Date:  2010-05-20       Impact factor: 4.375

Review 9.  Neurotransmitters as regulators of tumor angiogenesis and immunity: the role of catecholamines.

Authors:  Chandrani Sarkar; Debanjan Chakroborty; Sujit Basu
Journal:  J Neuroimmune Pharmacol       Date:  2012-08-11       Impact factor: 4.147

Review 10.  Nervous system regulation of the cancer genome.

Authors:  Steven W Cole
Journal:  Brain Behav Immun       Date:  2012-12-01       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.